{
    "2018-11-23": [
        [
            {
                "time": "2018-11-26",
                "original_text": "Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for November 26, 2018",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "Ex-Dividend",
                        "Scheduled"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-11-26",
                "original_text": "Novartis Gets Approval for Gene Therapy Luxturna in Europe",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Approval",
                        "Gene Therapy",
                        "Luxturna",
                        "Europe"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-26",
                "original_text": "Novartis's pricing might be tested with costly eye therapy",
                "features": {
                    "keywords": [
                        "Novartis",
                        "pricing",
                        "tested",
                        "costly",
                        "eye therapy"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-11-26",
                "original_text": "U.S. benefits manager baulks after Novartis values gene therapy at $4-5 million",
                "features": {
                    "keywords": [
                        "U.S.",
                        "benefits",
                        "manager",
                        "baulks",
                        "Novartis",
                        "gene therapy",
                        "$4-5 million"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-11-26",
                "original_text": "Spark Therapeutics' One-time Gene Therapy LUXTURNA Gets EU Approval",
                "features": {
                    "keywords": [
                        "Spark Therapeutics",
                        "One-time",
                        "Gene Therapy",
                        "LUXTURNA",
                        "EU",
                        "Approval"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-26",
                "original_text": "Novartis: EU Approves One-time Gene Therapy Luxturna To Restore Vision",
                "features": {
                    "keywords": [
                        "Novartis",
                        "EU",
                        "Approves",
                        "One-time",
                        "Gene Therapy",
                        "Luxturna",
                        "Restore",
                        "Vision"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-26",
                "original_text": "Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs",
                "features": {
                    "keywords": [
                        "Pharma",
                        "Stock",
                        "Roundup",
                        "Cancer",
                        "Approvals",
                        "PFE",
                        "ABBV",
                        "CHMP",
                        "Nod",
                        "Drugs"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}